One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third ...
Moderna (MRNA) will report its third-quarter earnings on November 5, after the closing bell, amid heated discussions around ...
Moderna (MRNA) shares have been in a massive uptrend in 2026, but options traders believe their rally could hit a pause after ...
Investors are thrilled with the results and the money that intismeran may bring in for Moderna in the future. CEO Stéphane ...
Moderna released full data on its closely watched cancer vaccine developed with Merck.
A US appeals court on Thursday grappled ​with how a federal law shielding companies from patent claims over products made for ...
Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite ...
WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 ...
The stock has soared 650% this year, largely outperforming many tech giants, the stocks that have driven positive market ...
Initial Phase 1/2 data highlight the potential of Moderna's multiplexed mRNA approach in relapsed or refractory ...
13don MSN
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...
The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results